6533b86ffe1ef96bd12cdd70
RESEARCH PRODUCT
Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies
M RondyE KisslingHd EmborgA GherasimR PebodyR TrebbienF PozoA LarrauriJ McmenaminM ValencianoB KaicS Kurecic FilipovicV Visekruna-vucinaI Pem NovoselZ LovricG PetrovićTg KrauseTk FischerB LinaAntonella FalchiAm VilcuC SoutyT BlanchonS Van Der WerfV EnoufS BehillilM ValetteS Bernard-stoecklinD Lévy-bruhlO LaunayP LoulergueN LenziZ LesieurAs L'honneurF GaltierC AgostiniC SerrandC MerleV FoulongneP VanhemsF LainéG LagathuF CarratS BudaU PreussK PrahmB SchweigerM WeddeA HeiderM MartinB BiereR DuerrwaldL DomeganL CoughlanJ O’donnellM JoyceC CollinsL DunfordJosè Manuel Martin MoranG TuiteM DuffyJ ConnellC De GascunC RizzoA BellaV AlfonsiMr CastrucciS PuzelliE PaganiV GhisettiE ParianiF BaldantiG PalùP D'agaroF AnsaldiP AffanniGm RossoliniB CamilloniP BagnarelliM SanguinettiL AtripaldiM ChironnaC SerraF VitaleM ChironnaC GerminarioA OrsiF AnsaldiI ManiniE MontomoliC NapoliGb OrsiI CasadoJ CastillaL FernandinoI Martínez-bazG EzpeletaA NavascuésA Pérez-garcíaA AguinagaC EzpeletaA MeijerS Van Den BrinkW Van Der HoekG GoderskiL WijsmanM BagheriF DijkstraM De LangeT MarzecP OverduinA TeirlinckE WentinkG DonkerS MarbusR Van Gageldonk- LafeberP Schneeberger Van Oosterheert JjV SchweitzerG GroeneveldB NunesCarlos Augusto Ribeiro MachadoAp RodriguesMaria Vanessa Diaz GomezI KislayaR GuiomarP PechirraP CristóvãoI CostaA PanarraR Côrte-realJ PoçasM João PeresA LarrauriA GherasimF PozoL García ComasMei MarisquerenaJc GalánD FolgueiraF Gonzalez CarrilR Sancho MartínezG CillaJ CastillaM García CenozA NavascuésC Quiñones RubioE Martinez OchoaM BlascoJ Gimenez DuranJm VanrellJ ReinaD CastrillejoA LarrauriAm GherasimC DelgadoJ OlivaI CasasA LarrauriAm GherasimF PozoI CasasM GarcíaM Latorre Milagro Beamonte AmA Martinez SapiñM Oribe AmoresA AizpurúaG CillaMarco MontesK ZakikhanyM BryttingÅ WimanA CarnahanR PebodyF WarburtonA DjennadJ EllisN AndrewsD MarquesS CottrellAlexander ReynoldsR GunsonM GalianoA LackenbyC RobertsonM O’dohertyM SinnathambyI YonovaC MooreM SartajS De LusignanJ McmenaminM ZambonM ValencianoA MorenE KisslingM RondyP. Penttinensubject
0301 basic medicineMalePediatricsEpidemiologyvirusesInfluenza B viruinfluenza ; influenza vaccine effectiveness ; influenza vaccination ; case control study ; multicentre study ; EuropeEurope case control study influenza influenza vaccination influenza vaccine effectiveness multicentre study0302 clinical medicineInfluenza A Virus H1N1 Subtype[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInteriminfluenza vaccine effectivenessEpidemiologyPandemicInfluenza A Virus030212 general & internal medicineQAInfluenza vaccine effectivenessChildmedia_commonVaccine EffectivenessVaccinationvirus diseasesMiddle Agedinfluenza vaccinationmulticentre study3. Good healthVaccinationEuropeTreatment OutcomeInfluenza VaccinesChild PreschoolH3N2 SubtypeFemaleSeasonsInfluenza VaccineinfluenzaRapid CommunicationHumanAdultRMmedicine.medical_specialtyAdolescentInfluenza vaccine030106 microbiologyCase control studyMulticentre studyEuropean studiesSettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA03 medical and health sciencesVirologyInfluenza Humanmedicinemedia_common.cataloged_instanceHumansH1N1 SubtypeVacina AntigripalEuropean UnionEuropean unionPreschoolPandemicsAgedPandemicInfluenza A Virus H3N2 SubtypeCuidados de SaúdePublic Health Environmental and Occupational HealthInfant NewbornInfantInfluenza ainfluenza vaccine effectivenecase control studyNewbornEurope; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre studyInfluenzarespiratory tract diseasesInfluenza vaccinationInfluenza B virusEurope; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre study; Adolescent; Adult; Aged; Child; Child Preschool; Europe; European Union; Female; Humans; Infant; Infant Newborn; Influenza A Virus H1N1 Subtype; Influenza A Virus H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza Human; Male; Middle Aged; Pandemics; Treatment Outcome; Vaccination; Seasons[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieDeterminantes da Saúde e da Doença[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinologydescription
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates. Funding: The five studies have received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446 to conduct the study in individuals aged 65 years or more. ECDC has contributed to fund some study sites of the EU-PC study under the Framework contract No ECDC/2014/026 for the individuals aged less than 65 years. All study teams are very grateful to all patients, general practitioners, paediatricians, hospital teams, laboratory teams, regional epidemiologists who have contributed to the studies. We acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s EpiFlu Database used for this study. All submitters of data may be contacted directly via the GISAID website www.gisaid.org Sí
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-03-01 |